6 September 2021

Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naïve EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential biomarkers for response

2021-09-06T18:27:18-07:00

*ASCO 2021* Background: Preliminary efficacy was observed with the combination of amivantamab, an EGFR-MET bispecific antibody, and lazertinib, a 3rd-generation

Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naïve EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential biomarkers for response2021-09-06T18:27:18-07:00
6 September 2021

Randomized phase III trial of aumolertinib vs gefitinib as 1st line treatment for EGFR exon 19 del or L858R mutations

2021-09-06T17:57:39-07:00

*ASCO 2021* Note: Could this become a less-expensive alternative to osimertinib? Background: Au is a novel, irreversible epidermal growth factor

Randomized phase III trial of aumolertinib vs gefitinib as 1st line treatment for EGFR exon 19 del or L858R mutations2021-09-06T17:57:39-07:00
24 June 2021

Durable Response of Leptomeningeal Disease With Osimertinib and Pemetrexed in EGFR-Mutated Metastatic NSCLC: A Case Report

2021-06-24T12:23:55-07:00

*April 2021* Optimal management of EGFR-mutated NSCLC with leptomeningeal (LM) disease progression through EGFR tyrosine kinase inhibitor remains unclear. We present a 39-year-old man with EGFR-mutated

Durable Response of Leptomeningeal Disease With Osimertinib and Pemetrexed in EGFR-Mutated Metastatic NSCLC: A Case Report2021-06-24T12:23:55-07:00
24 June 2021

EGFR-Mutated Metastatic NSCLC: Evolving Practice Standards and Opportunities for Improving Outcomes

2021-06-24T12:14:42-07:00

This is a great resource for newly-diagnosed EGFR lung cancer patients to learn from experts in this field about the

EGFR-Mutated Metastatic NSCLC: Evolving Practice Standards and Opportunities for Improving Outcomes2021-06-24T12:14:42-07:00
Go to Top